Previous 10 | Next 10 |
Halvorsen's 13F portfolio value increased from $27.68B to $36.37B. The number of positions increased from 86 to 96. Viking Global added UnitedHealth, AbCellera Biologics, Walt Disney, and Palo Alto Networks while dropping Analog Devices, CME Group, Comcast, and Exact Sciences. The...
Royalty Pharma plc (RPRX) Q4 2020 Earnings Conference Call February 17, 2021 8:00 AM ET Company Participants George Grofik - Senior Vice President, Head of Investor Relations and Communications Pablo Legorreta - Founder and Chief Executive Officer Jim Reddoch - Executive Vice President and Co...
Most investors would view Royalty Pharma (NASDAQ: RPRX) as a disappointment. The company conducted its much-heralded initial public offering (IPO) last year. Shares ended 2020 up only 12%, well below the major market indexes. Its stock is in negative territory so far this year. ...
Image source: The Motley Fool. Repros Therapeutics (NASDAQ: RPRX) Q4 2020 Earnings Call Feb 17, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Repros Therapeutics (RPRX) Q4 2020 Earnings Call Transcript
Double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Flow ( 2 ) $2.4 billion of acquisitions announced in 2020; maintained leading share of biopharma royalty funding market Increasing outlook for 2020-2025 Adjusted Cash Re...
Royalty Pharma (NASDAQ:RPRX) is scheduled to announce Q4 earnings results on Wednesday, February 17th, before market open.The consensus EPS Estimate is $0.70 and the consensus Revenue Estimate is $549.09M.Over the last 3 months, EPS estimates have seen 3 upward revisions and 0 downward. Reven...
[[ADI]], [[ALE]], [[ATH]], [[BCOR]], [[BPMC]], [[CHH]], [[COMM]], [[CRL]], [[DAVA]], [[DNOW]], [[EQT]], [[FUN]], [[GPC]], [[GRMN]], [[HEES]], [[HLT]], [[HSIC]], [[IRWD]], [[NI]], [[OC]], [[RPRX]], [[SAH]], [[SFL]], [[SHOP]], [[WING]], [[WIX]]For Seeking Alpha's full earnings season calendar, ...
Royalty Pharma is a unique entity in the healthcare ecosystem. The company is a royalty play as it acquires the rights to either late-stage products or commercially available entities. The goal is to capitalize on the long-term revenue generation of the product class before patent...
NEW YORK, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter 2020 financial results on Wednesday, February 17, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webcas...
NEW YORK and WALTHAM, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Minerva Neurosciences, Inc. (Nasdaq: NERV) today announced that Royalty Pharma will acquire Minerva’s royalty interest in seltorexant for an upfront payment of $60 million and up to $...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experie...
2024-07-24 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...